The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis

Chen, Wenjuan; Xu, Hui; Wang, Xiuxiu; Gu, Jun; Xiong, Huizi; Shi, Yu

doi:10.1016/j.intimp.2015.05.049

Cited by 40 publications

(31 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prowadzone są także badania, które mają udowodnić, że odpowiedź na leczenie może mieć podło-że genetyczne [36][37][38][39][40]. Jest ono związane z polimorfizmami genu TNF, receptora TNF-1B (TNFR1B) oraz genu TNFAIB3, jak również z polimorfizmami innych genów.…”

Section: Discussionunclassified

“…Jest ono związane z polimorfizmami genu TNF, receptora TNF-1B (TNFR1B) oraz genu TNFAIB3, jak również z polimorfizmami innych genów. W metaanalizie obejmującej 8 wyselekcjonowanych prac wykazano, że polimorfizm TNFRSF1B rs106162 wiąże się z brakiem odpowiedzi na inhibitory TNF-α [37]. Większość autorów uważa jednak, że koniecznie jest prowadzenie dalszych badań, aby potwierdzić wyniki w większej grupie pacjentów.…”

Section: Discussionunclassified

“…Studies are also conducted in order to verify whether response to treatment may be genetically conditioned [36][37][38][39][40]. It is associated with polymorphisms of the TNF gene, TNF receptor 1B (TNFR1B) and TNFAIB3 gene, as well as polymorphisms of other genes.…”

Section: Wnioskimentioning

confidence: 99%

“…It is associated with polymorphisms of the TNF gene, TNF receptor 1B (TNFR1B) and TNFAIB3 gene, as well as polymorphisms of other genes. A metaanalysis of eight selected studies has shown that the polymorphism of TNFRSF1B rs106162 is associated with non-response to TNF-α inhibitors [37]. The majority of authors, however, believe that further studies are needed to verify the results achieved to date in a larger group of patients.…”

Section: Wnioskimentioning

confidence: 99%

See 3 more Smart Citations

Challenges of biological therapy in patients with pustular psoriasis coexisting with psoriatic arthritis

Trelińska¹,

Woźniacka²,

Olejniczak-Staruch³

et al. 2017

View full text Add to dashboard Cite

Section: Discussionunclassified

Section: Wnioskimentioning

confidence: 99%

Section: Wnioskimentioning

confidence: 99%

See 2 more Smart Citations

Challenges of biological therapy in patients with pustular psoriasis coexisting with psoriatic arthritis

Trelińska¹,

Woźniacka²,

Olejniczak-Staruch³

et al. 2017

View full text Add to dashboard Cite

“…Recently, a meta-analysis investigated TNFRSF1B (rs1061622) and TNFRSF1A (rs7674559) polymorphisms in psoriasis patients. The investigated TNFRSF1A polymorphism showed no association with treatment response, but TNFRSF1B 676T allele was associated with beter response [51]. Another recent study published in 2015 included 518 psoriasis patients and 480 healthy controls, but only 90 patients were treated with biologic drugs.…”

Section: Pharmacogenetics Of Anti-tnfα Treatmentmentioning

confidence: 98%

Pharmacogenetics of Psoriasis Treatment

Redenšek¹,

Dolžan²

2017

An Interdisciplinary Approach to Psoriasis

View full text Add to dashboard Cite

Psoriasis is a chronic systemic, immune-mediated disorder of unknown aetiology, usually presenting with typical inlammatory skin lesions and/or joint manifestations, but systemic inlammation that may lead to the development of co-morbidities may also be present. First-line therapy encompasses local cutaneous treatment and phototherapy, but with more severe symptoms or systemic course, systemic treatment with methotrexate (MTX), immunosuppressant cyclosporine, retinoid acitretin or biologicals may be used. Treatment response varies between patients in terms of eicacy and/or toxicity, which could, among other reasons, be due to genetic diferences between patients. Approximately 10-30% of patients experience adverse drug reactions with MTX treatment, leading to discontinuation of MTX mostly due to hepatotoxicity. Around 15% of patients experience adverse events when treated with biologicals; however, the most frequent reason for discontinuation is ineicacy or loss of the initially favourable response over time. Ineicacy or occurrence of adverse drug reactions cannot be predicted, so genetic biomarkers of drug response in combination with clinical data could be helpful in treatment planning. Several polymorphic genes have already been associated with treatment outcome, most of them involved in drug metabolism, transport and target pathways. Genetic biomarkers could be helpful in personalized care of psoriasis patients in order to prevent adverse events or predict ineicacy of a certain drug.

show abstract

Development of a clinical model to predict secondary non-response of infliximab treatment in Crohn’s disease

Shen

Zheng

2020

Int J Colorectal Dis

View full text Add to dashboard Cite

The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis

Cited by 40 publications

References 44 publications

Challenges of biological therapy in patients with pustular psoriasis coexisting with psoriatic arthritis

Challenges of biological therapy in patients with pustular psoriasis coexisting with psoriatic arthritis

Pharmacogenetics of Psoriasis Treatment

Development of a clinical model to predict secondary non-response of infliximab treatment in Crohn’s disease

Contact Info

Product

Resources

About